Baird Capital Investor
Andrew, one of our non-executive board members, has close to 25 years’ experience in the private equity industry. He started his professional career at Price Waterhouse in 1986, where he qualified as a chartered accountant before moving into a corporate finance role. He joined North of England Ventures in 1993 to manage a regional investment fund before moving to Granville, subsequently Baird Capital Partners, in 1996. At Baird, he is responsible for investment activities in the UK with a particular focus on the business services and healthcare sectors and has held directorships in a large range of companies across these sectors.
Baird Capital Investor
Michael sits on our board of directors. He holds Bachelor’s and Master’s degrees in chemistry from the University of Bristol, where he graduated with First Class Honours. Michael began his career as a chemist working at GlaxoSmithKline and Synairgen. He then joined PricewaterhouseCoopers in its Transaction Services Team before spending time in Investment Banking at Spectrum Corporate Finance. Michael joined Baird Capital in 2014 and has a particular focus on technology and service-based businesses. During his time at Baird, Michael has spent time working in both London and Chicago. Michael is a chartered accountant.
Nader serves on Prescient’s Board as a Non-Executive Director. He has a BA from Georgetown University. He was previously the Chief Executive Officer of Campbell Alliance, where he oversaw all of the firm’s business units to ensure its continued growth, commitment to client service, development of new service lines and geographic expansion. Nader is an expert in developing and implementing business strategy, process improvement and business development solutions for clients in the pharmaceutical and biotechnology industries.
Dr. Arvind Raghunath
Arvind acts as an advisor to our software development team, connecting the development of technical components for our DSS platform with the business need, and has been with Prescient since 2010. He holds a medical degree and a PhD. He started his career as a research scientist at the International Centre for Neurotherapeutics in Dublin, where he focused on targeting and developing novel biopharmaceuticals for neurological conditions. He then moved to Vimta Labs, a leading Indian CRO, where he developed and tested biosimilars. At Prescient, Arvind has developed a unique understanding of the ever-evolving scientific, regulatory, clinical and market access environments.